Allergan's BOTOX Wins FDA Nod For Neurologic Condition-Associated Pediatric Detrusor Overactivity

The FDA has approved Allergan and AbbVie Inc's (NYSE: ABBV) BOTOX (onabotulinumtoxinA). It is used to treat detrusor (bladder muscle) overactivity associated with a neurologic condition in pediatric patients five years of age and older who have an inadequate response to or are intolerant of anticholinergic medication.
Neurogenic detrusor overactivity occurs when the spinal cord and bladder are not able to communicate effectively. As a result, the bladder muscle involuntarily contracts, increasing the bladder's pressure and reducing the bladder capacity, which can cause the individual to leak urine frequently and unexpectedly.
Price Action: ABBV share are down 0.68% at $104.68 on the last check Wednesday.

Momentum59.00

Growth40.11

Quality53.93

Value13.72

Short

Medium

Long